Global Opioids Agonist Drugs Market Progresses for Huge Profits by 2024

Global Opioids Agonist Drugs Market Set for Rapid
Growth And Trend by 2024
Global Opioids Agonist Drugs Market, By Product Type (Codeine, Fentanyl,
Meperidine, Methadone, Morphine, Hydrocodone), Therapeutic Application
(Pain Management, Cough Treatment, Diarrhea Treatment), and Geography -
Trends, Analysis and Forecast till 2024
Opioid drugs act on the opioid receptors present in the central and peripheral nervous system. The drug
class primarily used in relieving pain includes natural, semi-synthetic, and synthetic opioids. Codeine,
morphine, hydrocodone, oxycodone, heroin, and fentanyl are some of the major prescription drugs in
the global opioids agonist drugs market. Opioids can be administered as oral pills, parenteral, liquids,
patches, or lozenges. Overdose and drug abuse is a major concern for health regulators worldwide, with
the situation especially alarming in developed regions with easy access to these drugs. According to the
World Drug Report 2016, a staggering 17.4 million people were affected by opioid drug abuse. Drug
and health regulators are therefore, taking initiatives to govern pain prescriptions and curb the rate of
opioid abuse. The U.S. FDA considers all opioids as schedule 2 drugs—drugs that have high abuse
potential. In 2016, the CDC issued guidelines to prescribe opioids, limiting the daily dose of opioids to
90 morphine milligram equivalent (MME). The Global Opioids Agonist Drugs Market was valued at
US$ 17,132.5 million in 2015 and is expected to witness a moderate CAGR of 4.2% during the forecast
period (2016 – 2024).

Market Dynamics
According to the National Institutes of Health (NIH) estimates published in 2015 by the American Pain
Society, nearly 50 million people in the U.S. suffered from chronic pain. Use of opioids in cancer pain,
orthopedic pain, neuropathic pain, post-operative pain, and lower back pain is very effective. With
growing incidence of chronic pain, demand for opioids will also increase consequently.
Request For Sample Copy of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/135
North America is the largest market for opioids owing to availability of branded prescription and local
products, which inadvertently also leads to drug abuse. There are local unbranded products available
for every opioid derivative complementing the available prescription opioid brand. The Centers for
Disease Control and Prevention (CDC) states that 73% of all drug overdose deaths in the U.S. in 2015
were due to opioids (57% in 2010). Moreover, emergence of cannabis as an alternative to opioids and
legalization of the same in various regions is inhibiting the opioids market growth.
Increasing prevalence of chronic pain is expected to drive the opioids market growth
According to the American Academy of Pain Medicine (2011), the number of people who suffered
from chronic pain was around 1.8 billion. Moreover, according to the NIH estimates (2015), one in 10
people in the U.S. suffer from chronic pain. Around one-third to half of the population in the U.K.
suffers from chronic pain, according to a study published in the British Medical Journal in 2016.
Opioids are commonly used for treating pain, and opioid containing drugs are being misused or are
being consumed in overdose when patients follow self-medication. Moreover, rising prevalence of
pain, cough and, diarrhea are other factors driving growth of the opioids agonist drugs market. The
highly prescribed opioid in the U.S. is hydrocodone.
Key companies covered as a part of this study include Purdue Pharma L.P., Janssen Pharmaceuticals,
Inc., West - Ward Pharmaceuticals Corporation, Pfizer, Inc., Egalet Corporation, Allergan plc, Sanofi
SA, Boehringer Ingelheim, and Sun Pharmaceutical Industries Ltd.

Detailed Segmentation:
•Global Opioids Agonist Drugs Market, By Product Type:
•Codeine
•Fentanyl
•Meperidine
•Methadone
•Morphine
•Hydrocodone
•Global Opioids Agonist Drugs Market, By Therapeutic Application:
•Pain Management
•Neuropathic Pain
•Migraine
•Back Pain
•Osteoarthritis Pain
•Cancer Pain
•Others
•Cough Treatment
•Diarrhea Treatment
In recent times, cannabis has emerged as a potential alternative for opioids. Cannabis is legalized in
many states in the U.S. as it is considered safer than opioids. U.S. being a major consumer of such
drugs, legalizing cannabis (marijuana) is expected to have a detrimental impact on the opioids market
growth.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com